KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Quest Diagnostics (DGX) Cash from Investing Activities: 2009-2024

Historic Cash from Investing Activities for Quest Diagnostics (DGX) over the last 16 years, with Dec 2024 value amounting to -$2.5 billion.

  • Quest Diagnostics' Cash from Investing Activities rose 87.69% to -$201.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$942.0 million, marking a year-over-year increase of 56.39%. This contributed to the annual value of -$2.5 billion for FY2024, which is 140.15% down from last year.
  • Quest Diagnostics' Cash from Investing Activities amounted to -$2.5 billion in FY2024, which was down 140.15% from -$1.1 billion recorded in FY2023.
  • Over the past 5 years, Quest Diagnostics' Cash from Investing Activities peaked at $21.0 million during FY2021, and registered a low of -$2.5 billion during FY2024.
  • In the last 3 years, Quest Diagnostics' Cash from Investing Activities had a median value of -$1.1 billion in 2023 and averaged -$1.4 billion.
  • As far as peak fluctuations go, Quest Diagnostics' Cash from Investing Activities surged by 102.72% in 2021, and later slumped by 2,685.71% in 2022.
  • Yearly analysis of 5 years shows Quest Diagnostics' Cash from Investing Activities stood at -$772.0 million in 2020, then spiked by 102.72% to $21.0 million in 2021, then slumped by 2,685.71% to -$543.0 million in 2022, then plummeted by 95.40% to -$1.1 billion in 2023, then crashed by 140.15% to -$2.5 billion in 2024.